Kala Pharmaceuticals (KALA) is based in the Boston area, Massachusetts, and is focused on developing topical treatments for eye diseases using its proprietary MPP (Mucus Penetrating Particles) technology. Topically administered eye medications are usually trapped by the mucus in the tear film that covers the cornea, thus limiting the drug's access to the eye tissues. The MPP technology allows the drug to penetrate the mucus in the tear film effectively, thus creating a potential for lower dose or less frequent dosing. The technology has origins in MIT Labs.
The first product candidate from